CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Venezuela
Summary
Venezuela ranked 187 out of 190 countries in ease of doing business. In July 2017, rating firm Standard & Poor’s downgraded Venezuela’s economy to CCC with a negative outlook. Moody’s also downgraded its rating to Caa3 with a negative outlook, while Fitch rated it at CCC with a negative outlook.
Venezuela is one of the emerging pharmaceutical markets in South America, with a major dependence on imports. However, economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers. The value of the market was US$12.6 Billion in 2015, having increased from US$5.7 Billion in 2009, at a Compound Annual Growth Rate (CAGR) of 14.1%. Drug prices in Venezuela are considerably higher than the regional average of US$7.86; in 2016, the average drug price in Venezuela was US$21.95, which was the highest in the entire Latin America region.
Medical device market is also mainly dependent on imported products. The US is the major supplier for medical devices, although in recent times Cuba, Mexico and Brazil have replaced some of the US exports. Disposable healthcare items such as syringes, surgical cloths and hospital furniture are manufactured domestically.
The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Venezuela” is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Venezula. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure.
In particular, this report provides the following –
– Provides an overview of the pharmaceutical and medical device market of Venezuela, including the market size; market segmentation by generic, Over-The-Counter (OTC), biologic and biosimilar products; and the key drivers and barriers for the market.
– Covers the country’s reimbursement and payer landscape, as well as the regulatory landscape. The reimbursement and payer landscape section elaborates on the features of the healthcare reimbursement process for Venezuela.
– Provides a detailed analysis of the political and economic environment of Venezuela. It analyzes its economic indicators, demographics, healthcare infrastructure and healthcare expenditure.
– Provides an overview of the opportunities and challenges for growth that exist in the healthcare market of Venezuela.
Scope
The report provides information on the healthcare, regulatory, and reimbursement landscape in Venezuela, and includes –
– An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
– Profiles and SWOT analyses of the major players in the pharmaceutical market: Bayer, Abbott, Sanofi, Novartis and Merck & Co.
– An insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
– Detailed analysis of the country’s political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
– An overview of the opportunities for and challenges to growth in the Venezuelan healthcare market.
Reasons to buy
This report will enhance your decision-making capability by allowing you to –
– Develop business strategies by understanding the trends shaping and driving Venezuela’s healthcare market
– Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments and companies likely to impact Venezuela’s healthcare market in the future
– Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance
– Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership